...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Pharmaceutical Biotechnology >Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients
【24h】

Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients

机译：甲氧基聚乙二醇-依泊汀β作为一种新型的促红细胞生成剂，对非透析性慢性肾脏病患者可能具有肾脏保护和心血管保护作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic kidney disease (CKD) is an important health problem, because of unsuccessful outcomes such as CKD progression to end stage renal disease and high risk of cardiovascular disease (CVD). Anemia, associated with CKD, is considered a non-traditional risk factor for CVD which may contribute to faster CKD progression. Anemia treatment with erythropoiesis-stimulating agents (ESAs) seems to exert non-hematopoietic effects on different tissues and organs, including cardiovascular system and kidneys. On the other hand, clinical use of high doses of short-acting ESAs and higher target hemoglobin level were associated with higher risk of CVD. Literature data indicate the usefulness of long-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuous erythropoietin receptor activator seems to be a good choice in these patients because of its efficiency, safety and monthly administration. Continuous but slower erythropoietin receptor activation, using methoxy polyethylene glycol-epoetin beta (MPG-EPO), administered once a month, slowly corrects anemia without exceeding the recommended hemoglobin level. An overview of the available literature may suggest nephroprotective and cardiovascular protective effects of MPG-EPO. It seems possible that anemia treatment with a novel ESAs, MPG-EPO in early stages of CKD may reduce CVD risk in these patients and delay CKD progression. This review of available literature evaluates the correlation between continuous erythropoietin receptor activation using MPG-EPO and CKD progression and CVD risk in non-dialysis CKD patients.
机译：慢性肾脏病（CKD）是一个重要的健康问题，因为结局不成功，例如CKD进展至终末期肾脏疾病和心血管疾病（CVD）的高风险。与CKD相关的贫血被认为是CVD的非传统危险因素，可能有助于更快的CKD病情发展。用促红细胞生成素（ESA）治疗贫血似乎对包括心血管系统和肾脏在内的不同组织和器官产生非造血作用。另一方面，临床上使用大剂量的短效ESA和更高的目标血红蛋白水平与CVD的风险更高有关。文献数据表明长效ESA在非透析CKD患者贫血治疗中的有用性。尤其是，连续促红细胞生成素受体激活剂似乎是这些患者的好选择，因为它的有效性，安全性和每月给药。每月一次使用甲氧基聚乙二醇-表皮素β（MPG-EPO）持续但较慢地促红细胞生成素受体活化，可缓慢纠正贫血，且不超过推荐的血红蛋白水平。现有文献的概述可能提示MPG-EPO的肾保护作用和心血管保护作用。在CKD的早期阶段，用新型ESA，MPG-EPO进行贫血治疗似乎可以降低这些患者的CVD风险并延迟CKD的进展。这篇有关现有文献的综述评估了非透析CKD患者使用MPG-EPO持续促红细胞生成素受体激活与CKD进展与CVD风险之间的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号